Market research
BCART.BR Biocartis Group NV
BR EUR Healthcare
Latest close
As of 20 Feb 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 27M
- P/E ratio
- Not available
- Analyst target
- 0
- Dividend yield
- Not available
- Beta
- 1.32
Profile
Instrument facts
- Exchange
- BR
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- BE0974281132
- Market cap
- 27M
- P/E ratio
- Not available
- Analyst target
- 0
- Dividend yield
- Not available
- Beta
- 1.32
About
About Biocartis Group NV
Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-CoV-2/Flu/RSV panels and SARS-CoV-2 tests, as well as SeptiCyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with GeneproDx for the development of ThyroidPrint novel genomic test on the Idylla platform; and collaboration with APIS Assay Technologies Ltd. to develop and commercialize breast cancer subtyping test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium.
Research context
Biocartis Group NV appears in PyInvesting’s Brussels Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the BCART.BR discussion.
5 years, 6 months ago
Biocartis Group NV is currently in a long term downtrend where the price is trading 15.8% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.8.
Biocartis Group NV's total revenue sank by 17.7% to $17M since the same quarter in the previous year.
Its net income has increased by 8.3% to $-32M since the same quarter in the previous year.
Finally, its free cash flow grew by 45.9% to $-8M since the same quarter in the previous year.
Based on the above factors, Biocartis Group NV gets an overall score of 3/5.